Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

T790M mutation

This page shows the latest T790M mutation news and features for those working in and with pharma, biotech and healthcare.

AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan

AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan

for patients with inoperable or recurrent epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). ... Dave Fredrickson, Executive Vice President, Head of the Oncology Business Unit, AstraZeneca, said: “Tagrisso is

Latest news

  • AZ speeds first-line lung cancer filing for Tagrisso to EMA AZ speeds first-line lung cancer filing for Tagrisso to EMA

    Tagrisso has been growing fast in its approved indication as a second-line therapy for EGFR-positive NSCLC after patients develop resistance (the T790M mutation) and progress on Iressa or Tarceva, ... Conversely, others argue that this denies patients

  • AZ gets rapid approval in China for Tagrisso AZ gets rapid approval in China for Tagrisso

    Tagrisso (osimertinib) - a third-generation EGFR inhibitor - has been approved by the China Food and Drug Administration (CFDA) as a second-line treatment for EGFR T790M mutation-positive metastatic non-small ... Last December, AZ reported head-to-head

  • AZ's Tagrisso beats chemotherapy in lung cancer trial AZ's Tagrisso beats chemotherapy in lung cancer trial

    to standard therapy in patients with T790M mutation-positive, locally-advanced or metastatic NSCLC. ... Tagrisso is a third-generation EGFR inhibitor and was the first drug to be approved to treat patients with metastatic EGFR T790M mutation-positive

  • Reformed Cancer Drugs Fund backs its first drug - AZ’s Tagrisso Reformed Cancer Drugs Fund backs its first drug - AZ’s Tagrisso

    In the meantime, the recently-relaunched CDF will give around 300 patients across England and Wales access to Tagrisso as a second-line treatment for advanced metastatic EGFR T790M mutation-positive ... This is the system working as it should.”.

  • FDA panel says no to quick approval of Clovis' rociletinib FDA panel says no to quick approval of Clovis' rociletinib

    Rociletinib is under review for the treatment of non-small cell lung cancer (NSCLC) patients whose tumours are epidermal growth factor receptor (EGFR) positive and carry the T790M resistance mutation. ... T790M is the most commonly encountered and

More from news
Approximately 1 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    There is a good reason why Tagrisso was chosen for the fast track – the drug is for patients with epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung ... The EGFR mutation is particularly prevalent in Asian populations

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    resistance mechanisms for first and second generation inhibitors is the emergence of T790m, which basically switches on that same pathway again. ... Another development is AZD9291 – a drug which addresses the T790M mutation, which is a key resistance

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A specialist Advertising and Med Comms agency dedicated to bringing much-needed creativity to healthcare marketing. We believe that brilliant ideas...

Latest intelligence

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
...
New Playbook Alert: Virtual Patient Engagement
...
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...

Quick links